CTLA4 and neoplasm: Thus, to overcome tumor resistance, various studies have evaluated new potential markers that converge to discriminate between responders and non-responders to anti-PD-1/anti-CTLA-4 therapy, helping to stratify patients suitable for the most effective immunotherapy [17].